Thus, overexpression of Nrf2 due to Keap1 loss may confer resistance to cisplatin, a widely used chemotherapy regimen for head and neck cancer, by regulating ROS and cancer stem cell pathways. This evidence concerns the gene NFE2L2 and head and neck cancer.